Formoterol fumarate dihydrate
Formoterol, the active substance of Oxis Turbuhaler, is a selective β2-agonist.
Its action is based on the relaxation of smooth muscles in the bronchi. This makes breathing easier.
When inhaling through the mouthpiece of the inhaler, the medicine gets into the lungs. The action of the medicine
starts within 1 to 3 minutes after inhalation and lasts for 12 hours.
Oxis Turbuhaler is indicated for the maintenance treatment, in combination with inhaled glucocorticosteroids, of symptoms of airway obstruction and for the prevention of symptoms caused by exercise in patients with asthma, if treatment with glucocorticosteroids is not sufficient.
Oxis Turbuhaler is also indicated for the treatment of symptoms of airway obstruction in patients with chronic obstructive pulmonary disease (COPD).
Oxis Turbuhaler is not intended for the initiation of asthma treatment, as it is not sufficient for this purpose.
Use of Oxis Turbuhaler should not be started during an acute, severe asthma exacerbation or during worsening of existing exacerbation. During treatment, exacerbations and serious side effects related to the course of asthma may occur.
If there is no improvement in symptoms after starting treatment or if exacerbation occurs, the patient should continue to take the medicine and consult the doctor who prescribed it.
The patient should inform the doctor about any worrying reactions that have occurred in the past after using formoterol or lactose, or after taking other medicines. In some cases, Oxis Turbuhaler should be used with caution. The patient should especially inform the doctor about heart disease, diabetes, thyroid function disorders (hyperthyroidism), pheochromocytoma, hypertension, aneurysm, and decreased potassium levels in the blood.
If bronchospasm occurs after using the medicine, the patient should stop using it immediately and consult a doctor.
Oxis Turbuhaler should be used in the treatment of asthma together with glucocorticosteroids.
The patient should continue to take glucocorticosteroids after starting Oxis Turbuhaler, even if symptoms improve. In case of an acute asthma attack, additional doses of Oxis Turbuhaler can be used. However, if it is necessary to use additional doses of Oxis Turbuhaler more frequently than usual to relieve breathing difficulties, the patient should consult their doctor immediately. In such a case, additional treatment may be necessary.
In patients with diabetes, the doctor may recommend monitoring blood glucose levels during the initial treatment period.
In patients with severe asthma who are taking other medicines, the doctor may recommend monitoring potassium levels in the blood.
The patient should strictly follow the doctor's recommendations and not change them without prior consultation.
Oxis Turbuhaler should not be used in children under 6 years of age due to insufficient data on the use of the medicine in this age group.
Other medicines used at the same time may affect the action of Oxis Turbuhaler.
The patient should tell their doctor about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take, including those available without a prescription.
Especially, the patient should inform the doctor if they are taking any of the following medicines:
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a baby, they should consult their doctor before using this medicine.
If a woman using Oxis Turbuhaler becomes pregnant, she should inform her doctor as soon as possible.
It is not known whether formoterol passes into breast milk, so Oxis Turbuhaler should not be used by breastfeeding mothers.
Using Oxis Turbuhaler does not affect the ability to drive or use machines.
If the patient has previously been diagnosed with intolerance to some sugars, they should consult their doctor before taking the medicine.
One dose of Oxis Turbuhaler 9 micrograms/dose contains 891 micrograms of lactose monohydrate, which is usually of no clinical significance in patients with lactose intolerance.
Lactose monohydrate contains small amounts of milk proteins. These may cause allergic reactions.
Oxis Turbuhaler should always be used as directed by the doctor. If there are any doubts, the patient should consult their doctor. The dosage of Oxis Turbuhaler is determined individually.
Oxis Turbuhaler can be used in patients with asthma once or twice a day (maintenance doses) or as needed to relieve breathing difficulties.
Adults over 18 years of age
1 inhalation to relieve breathing difficulties.
1 inhalation once or twice a day. In some patients, it may be necessary to use 2 inhalations once or twice a day.
1 inhalation before exercise.
The maximum daily maintenance dose of Oxis Turbuhaler should not exceed 4 inhalations, but up to 6 inhalations per day may be used if necessary.
The maximum single dose is 3 inhalations.
Children aged 6 and over
1 inhalation to relieve breathing difficulties.
1 inhalation once or twice a day.
1 inhalation before exercise.
The maximum daily maintenance dose of Oxis Turbuhaler should not exceed 2 inhalations, but up to 4 inhalations per day may be used if necessary.
The maximum single dose is 1 inhalation.
The doctor will monitor the patient's asthma and adjust the dose of Oxis Turbuhaler, gradually reducing it to the smallest dose that controls the asthma.
However, the patient should not change the dose of the medicine without prior consultation with their doctor.
Adults over 18 years of age
1 inhalation once or twice a day.
The maximum daily maintenance dose should not exceed 2 inhalations.
In patients treated with Oxis Turbuhaler, additional doses (inhalations) may be used as needed, in addition to the maintenance treatment, to relieve symptoms.
The maximum daily maintenance dose is 4 inhalations (including those used regularly).
The maximum single dose is 2 inhalations.
Special patient groups
No dose adjustment of Oxis Turbuhaler is necessary in elderly patients, patients with liver or kidney function disorders, if the recommended doses are used.
Note:
The need to use additional doses (inhalations), in addition to the maintenance treatment, more than 2 times a week indicates that the treatment is insufficient.
In such a case, the patient should consult their doctor as soon as possible.
Before starting treatment with Oxis Turbuhaler, the patient should read the “Instructions for use of Oxis Turbuhaler”below.
Due to the very small amount of powdered active substance in the delivered dose, the patient may not feel the taste of the medicine after inhalation. However, if the patient follows the instructions, they can be sure that the prescribed dose has been taken and the medicine is in the lungs.
Before firstuse of a newOxis Turbuhaler inhaler, the patient should prepare it for use as follows:
To perform an inhalation, the patient should follow the instructions below each time.
As with all inhalers, caregivers should ensure that children who have been prescribed Oxis Turbuhaler use the correct inhalation technique, as described above.
The patient should wipe the outside of the mouthpiece with a dry cloth once a week. Do not use water or other liquids to clean the inhaler.
Note:
Overdose may cause the following symptoms: muscle tremors, headaches, rapid heartbeat, dizziness, drowsiness.
If the patient has taken a higher dose of the medicine than recommended, they should immediately consult their doctor or go to the hospital.
Oxis Turbuhaler inhalation powder should be used as directed by the doctor and only the prescribed number of doses should be taken. The patient should not take a double dose to make up for a missed dose.
If the patient has any further doubts about using the medicine, they should consult their doctor or pharmacist.
Like all medicines, Oxis Turbuhaler can cause side effects, although not everybody gets them.
As with other inhaled medicines, very rarely (less than 1 in 10,000 patients), paradoxical bronchospasm may occur. If bronchospasm occurs after using the medicine, the patient should stop using it and consult their doctor immediately.
Common side effects (in 1 to 10 patients in 100)
Uncommon side effects (in 1 to 10 patients in 1,000)
Rare side effects (in 1 to 10 patients in 10,000)
Very rare side effects (less than 1 in 10,000 patients)
If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
By reporting side effects, more information can be collected on the safety of the medicine.
Side effects can also be reported to the marketing authorization holder.
Store out of sight and reach of children.
There are no special precautions for storage.
The inhaler should be stored with the cap tightly closed.
Do not use Oxis Turbuhaler after the expiry date stated on the carton and the label on the Turbuhaler.
The expiry date refers to the last day of the month.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The carton contains one inhaler, which holds 60 doses of the medicine.
Each inhaler is additionally labeled with:
“60 DOSES FORMOTEROL 9 μg/DOSE
LOT/LOTE ZM 1234
EXP/CAD MM-YYYY”,
which means:
“60 DOSES OF FORMOTEROL 9 μg/DOSE
SERIAL NUMBER ZM 1234
EXPIRY DATE: MM-YYYY”
AstraZeneca AB
S-151 85 Sodertalje
Sweden
AstraZeneca AB
Forskargatan 18
SE-151 36 Södertälje
Sweden
To obtain more detailed information, the patient should contact the representative of the marketing authorization holder:
AstraZeneca Pharma Poland Sp. z o.o.
ul. Postępu 14
02-676 Warsaw
tel: +48 22 245 73 00
fax: +48 22 485 30 07
Date of last revision of the leaflet:June 2023
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.